NCT04916002
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients who have had more than 5 lines of systemic therapy; Patients who have received previous CMP-001 treatment; Patients with untreated, symptomatic, or enlarging central nervous system metastases including leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT04916002